530 results about "Tricyclic" patented technology

The invention belongs to the field of perovskite solar cells, and particularly relates to application of a bulk phase and interface synergistic passivator in a perovskite solar cell. The invention provides a bulk phase / interface synergistic passivation innovative strategy, molecules with a tricyclic sulfur-nitrogen heterocyclic ring structure are introduced as a synergistic passivator, and defect global repair of each functional layer of a device is realized. The molecular design of the structural derivative taking phenothiazine as the core has the following advantages: skeleton characteristics: a conjugated tricyclic system forms an electron transport network through pi-pi stacking, endows molecules with excellent electron delocalization ability, and effectively regulates and controls carrier kinetics; the thioether group is used for dynamically repairing an ion migration channel through oxidation-reduction activity and inhibiting formation of deep-energy-level defects; and the secondary amine group is used as a hydrogen bond donor for anchoring uncoordinated halide ions and synchronously passivating surface and grain boundary defects.

The present application relates to a novel tricyclic derivative compound as a KRAS mutant protein inhibitor, and use thereof. The compound according to one embodiment of the present application inhibits the activity of a KRAS mutant protein and thus can be used in the prevention or treatment of diseases induced by KRAS mutation.

Disclosed are compounds of Formula I (shown below), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Provided are a fused tricyclic compound, a preparation method therefor and a pharmaceutical use thereof. Specifically, provided are a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use as an RAS inhibitor and a use in the preparation of a drug for treating and / or preventing RAS-mediated or RAS-dependent diseases or disorders. The groups in general formula (I) are as defined in the description.

Disclosed are compounds of Formula I, shown below, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Processes and methods of preparing Compound (I) are disclosed. Crystalline forms of Compound (I), pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1 to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

The present disclosure is directed to compounds of Formula I:and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

Provided herein are methods for preparing SERD tricyclic compounds having a substituted phenyl or pyridyl moiety. Provided herein are methods for preparing intermediate compounds of Formula (II) and compounds of Formula (I) useful in the treatment of cancer. # imgabs0 #

The invention discloses a polyfunctional rosin-based reactive diluent. The structural formula of the polyfunctional rosin-based reactive diluent is shown as a formula (I) or a formula (II). The polyfunctional rosin-based reactive diluent has a rigid tricyclic diterpenoid structure of rosin, is small in molecular weight and low in viscosity, can be used for preparing an ultraviolet curing material, has excellent hardness and scratch resistance after light curing and film forming, and is simple in preparation method, low in cost and suitable for industrial production. And a polycarboxylic acid functional group is efficiently constructed under a mild condition.

The disclosure provides substituted nitrogen containing tricyclic compounds as PARP inhibitors and the use thereof. This disclosure provides compounds represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, Z3, Z4, Z5, A1, A2, A3, L, m, n, ring B and Cy are defined herein. The compounds of Formula I of the present disclosure are PARP inhibitors and thus are useful in the treatment of diseases, disorders and conditions, such as cancer, responsive to the inhibition of PARP activity. The present disclosure also relates to a pharmaceutical composition comprising the compound of Formula I and the use of the compound of Formula I in the preparation of a medicament for the treatment or prevention of diseases or conditions responsive to the inhibition of PARP activity.

The invention relates to a sustained-release pharmaceutical preparation of a fused tricyclic gamma-amino acid derivative and a preparation method of the sustained-release pharmaceutical preparation. The fused tricyclic gamma-amino acid derivative is a compound as shown in a formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof.

Provided is an aggregate amount regulator having an excellent aggregate production promoting effect. Use of a compound selected from the group consisting of 4-ethyl-alpha, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta The compound is at least one compound selected from the group consisting of alpha, alpha-dimethyl benzene propionaldehyde, 1-(2-tert-butylcyclohexyloxy)-2-butanol, benzyl benzoate, tricyclodecenyl acetate, trichloromethyl phenyl methyl acetate, geraniol, cyclohexylidene (phenyl) acetonitrile, 1-menthol, linacol, dihydromyrcenol, benzyl salicylate, 4-(5, 5, 6-trimethylbicyclo [2.2. 1] heptane-2-yl) cyclohexanol, and the like.

This invention provides an siRNA nucleic acid pesticide targeting the DICER2 gene to control rice blast fungus, belonging to the field of biotechnology. The siRNA molecule can delay and inhibit the formation of rice blast fungus appressoria, thereby reducing the pathogenicity of the fungus and providing a new method for controlling rice blast. When used in combination with tricyclazole or clotrimazole, it has a synergistic effect. The siRNA molecule targeting the DICER2 gene is prepared into a nucleic acid pesticide and sprayed on rice leaves, effectively reducing rice blast lesions and their area, thus enabling its use in rice blast control. Furthermore, it avoids the cumbersome process of cultivating genetically modified crops and addresses consumer concerns.

The invention relates to the technical field of medicines, in particular to fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutically acceptable salts, stereoisomers, pharmaceutical compositions and application thereof. The structure of the fused tricyclic substituted isoxazolidinyl urea derivative is as shown in a formula (I). The fused tricyclic substituted isoxazolidinyl urea derivative disclosed by the invention has obvious TrkA kinase and cell inhibition activity and selective inhibition activity.

Disclosed are tricyclic fused heterocyclic compounds with PDE3 / 4 dual inhibition effect shown in formula (I), and stereoisomers, solvates, or pharmaceutically acceptable salts thereof, and use thereof in the preparation of drugs for treating / preventing PDE3 / 4 mediated diseases, wherein the groups in formula (I) are as defined in the specification.

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

The present invention relates to solid phase pharmaceutical compositions of 6′-fluoro-N-(4-fluorobenzyl)-4′-oxo-3′,4′-dihydro-1′H-spiro[piperidine-4,2′-quinoline]-1-carboxamide that is useful as a AKR1C3 dependent KARS inhibitor. The present invention also relates to processes for the preparation of said pharmaceutical compositions of said compound, methods of using said pharmaceutical compositions in the treatment of various diseases and disorders, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

The application belongs to the field of genetic engineering and biosynthesis, and particularly relates to biosynthesis of a class of diterpenoids. The application provides genes having a key role in the formation of a 5-8-5 tricyclic mother nucleus and a five-membered heterocyclic ring in biosynthesis of the class of diterpenoids, which are respectively named as PrcA and PrcB and polypeptides encoded by the genes, expression of PrcA and PrcB is carried out through a heterologous expression system of Aspergillus oryzae, and five diterpenoids with novel structures and anti-metabolic related fatty liver disease activity are obtained. The application provides application of the polypeptides in biosynthesis of the class of diterpenoids, and enriches a diterpenoid library, thereby providing lead compound resources for discovering new anti-metabolic related fatty liver disease medicinal raw materials.

The present invention relates to compounds having a fused, substituted tricyclic scaffold and stereo-isomeric forms, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted tricyclic derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said substituted tricyclic derivatives have been identified as especially potent ligands of FK506 binding proteins (FKBPs), especially human FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMip, CtMip, CpMip, NgMip, KpMip, BpMip, TcMip, EcFKLB, EcFKPA, PaFKLB, PaFKPA, AbFKLB, AbFKPA, and are useful for treatment of diseases such as psychiatric, metabolic, infective, neurological and haematological disorders as well as pain and cancers and as anti-inflammatory drugs. Said substituted tricyclic derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues.

Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.

The present invention relates to tricyclic compounds of formula (I), pharmaceutical compositions comprising same, preparation methods therefor, and uses thereof, wherein each variable is as defined in the description.

The invention relates to a fused tricyclic cyclin-dependent kinase inhibitor as well as a preparation method and medical application thereof. Particularly, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown as a formula I, and the definition of each substituent group is shown in the specification. The fused tricyclic cyclin-dependent kinase inhibitor is used for preventing and / or treating diseases related to cyclin-dependent kinase, especially cancers.

A process for upgrading a pyrolysis oil comprising contacting a pyrolysis oil feed with hydrogen in a first fixed bed reactor in the presence of a mixed metal oxide catalyst wherein: the pyrolysis oil feed comprises a polycyclic aromatic hydrocarbon compound comprising greater than or equal to 16 carbon atoms; and contacting the pyrolytic oil feedstock with hydrogen in the presence of a mixed metal oxide catalyst in a first fixed bed reactor to convert at least a portion of the polycyclic aromatic hydrocarbon compounds in the pyrolytic oil feedstock into bicyclic aromatic hydrocarbon compounds, tricyclic aromatic hydrocarbon compounds, or both, passing the intermediate stream comprising the bicyclic aromatic compound, the tricyclic aromatic compound, or both to a second fixed bed reactor downstream of the first fixed bed reactor; and contacting the intermediate stream with hydrogen in the presence of a mesoporous supported metal catalyst in a second fixed bed reactor.

The present invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions containing said compounds, processes for the preparation of said compounds, and the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7), and their use in the treatment of diseases, such as cancer. [Formula 1] TIFF2023554673000617.tif33128

Provided are novel chiral aromatic diazatricyclo-compounds and pharmaceutically acceptable salts thereof, that are smooth muscle myosin 2 specific inhibitors useful for the treatment of ischemic events and conditions associated with capillary no-reflow, or other smooth-muscle related symptoms.

The invention belongs to the technical field of pesticides, and relates to 11 bactericide compositions for mainly preventing and treating crop diseases caused by pyricularia oryzae and colletotrichum gloeosporioides. The compound YJY-22 provided by the invention is novel in structure and unique in action mode, and has no cross resistance with isoprothiolane, fenoxanil, pyraclostrobin, tricyclazole, azoxystrobin, mancozeb, captan, difenoconazole, prochloraz, chlorothalonil and tebuconazole. As the action mechanism of the compound YJY-22 is different from that of the medicament, and the compound YJY-22 and the medicament have no cross resistance, the compound YJY-22 and the medicament are compounded, so that the sterilization range can be expanded, the sterilization effect can be enhanced, the drug resistance of phytopathogen can be delayed, the safety to crops is good, the prevention and control spectrum is expanded, and the requirements of pesticide reduction and synergism are met.